High nuclear expression of HDGF correlates with disease progression and poor prognosis in human endometrial carcinoma

Disease Markers

Volumn 2014, Issue , 2014, Pages

  Wang, Lijing ^a   Jiang, Qingping ^b,c   Hua, Shengni ^b   Zhao, Mengyang ^b   Wu, Qiangyun ^b   Fu, Qiaofen ^b   Fang, Weiyi ^b   Guo, Suiqun ^a  

^a THE THIRD AFFILIATED HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATOMA DERIVED GROWTH FACTOR; HEPATOMA-DERIVED GROWTH FACTOR; SIGNAL PEPTIDE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER TISSUE; CELL NUCLEUS; CLINICAL FEATURE; CYTOPLASM; DISEASE ASSOCIATION; ENDOMETRIUM CARCINOMA; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; VERY ELDERLY; CARCINOMA; DISEASE COURSE; ENDOMETRIUM; ENDOMETRIUM TUMOR; GENE EXPRESSION; GENETICS; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; METABOLISM; MORTALITY; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SECONDARY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; CELL NUCLEUS; DISEASE PROGRESSION; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; GENE EXPRESSION; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TUMOR MARKERS, BIOLOGICAL;

EID: 84896906515     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2014/298795     Document Type: Article

References (25)

1. Carlson J. W., Mutter G. L., Endometrial intraepithelial neoplasia is associated with polyps and frequently has metaplastic change. Histopathology 2008 53 3 325 332 2-s2.0-50049127811 10.1111/j.1365-2559.2008.03104.x
2. Jemal A., Bray F., Center M. M., Ferlay J., Ward E., Forman D., Global cancer statistics. CA. Cancer Journal for Clinicians 2011 61 2 69 90 2-s2.0-79952232216 10.3322/caac.20107
3. Jemal A., Tiwari R. C., Murray T., Ghafoor A., Samuels A., Ward E., Feuer E. J., Thun M. J., Cancer statistics. CA. Cancer Journal for Clinicians 2004 54 1 8 29 2-s2.0-1542348477
4. Yu F., Jiang Q. P., Zhou Y., Abnormal expression of matrix metalloproteinase-9 (MMP9) correlates with clinical course in Chinese patients with endometrial cancer. Disease Marker 2012 32 321 327
5. Nakamura H., Izumoto Y., Kambe H., Kuroda T., Mori T., Kawamura K., Yamamoto H., Kishimoto T., Molecular cloning of complementary DNA for a novel human hepatoma-derived growth factor. Its homology with high mobility group-1 protein. The Journal of Biological Chemistry 1994 269 40 25143 25149 2-s2.0-0028043462
6. Everett A. D., Bushweleer J., Hepatoma derived growth factor is a nuclear targeted mitogen. Current Drug Targets 2003 4 5 367 371 2-s2.0-0038205701 10.2174/1389450033490975
7. Yoshida K., Nakamura H., Okuda Y., Expression of hepatoma-derived growth factor in hepatocarci-nogenesis. Journal of Gastroenterology and Hepatology 2003 18 1293 1301
8. Hu T. H., Huang C. C., Liu L. F., Expression of hepatoma-derived growth factor in hepat ocellular carcinoma. Cancer 2003 98 1444 1456
9. Huang J., Chao C., Su T., Yeh S., Chen D., Chen C., Chen P., Jou Y., Diverse cellular transformation capability of overexpressed genes in human hepatocellular carcinoma. Biochemical and Biophysical Research Communications 2004 315 4 950 958 2-s2.0-1342324080 10.1016/j.bbrc.2004.01.151
10. Ren H., Tang X., Lee J. J., Feng L., Everett A. D., Waun K. H., Khuri F. R., Mao L., Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer. Journal of Clinical Oncology 2004 22 16 3230 3237 2-s2.0-4344714365 10.1200/JCO.2004.02.080
11. Bernard K., Litman E., Fitzpatrick J. L., Shellman Y. G., Argast G., Polvinen K., Everett A. D., Fukasawa K., Norris D. A., Ahn N. G., Resing K. A., Functional proteomic analysis of melanoma progression. Cancer Research 2003 63 20 6716 6725 2-s2.0-0142219891
12. Wang S., Fang W., Increased expression of hepatoma-derived growth factor correlates with poor prognosis in human nasopharyngeal carcinoma. Histopathology 2011 58 2 217 224 2-s2.0-79951671375 10.1111/j.1365-2559.2010.03739.x
13. Ioachim E. E., Goussia A. C., Kitsiou E. G., Charalabopoulos K., Mermiga E., Stefanaki S., Immunohistochemical expression of retinoblastoma gene product in normal, hyperplastic and malignant endometrium. Correlation with p53 protein expression, c-erbB-2, hormone receptors' status and proliferative activity. Disease Markers 2002 18 3 143 152 2-s2.0-0036444468
14. Lacey J. V., Sherman M. E., Rush B. B., Ronnett B. M., Ioffe O. B., Duggan M. A., Glass A. G., Richesson D. A., Chatterjee N., Langholz B., Absolute risk of endometrial carcinoma during 20-year follow-up among women with endometrial hyperplasia. Journal of Clinical Oncology 2010 28 5 788 792 2-s2.0-77649205666 10.1200/JCO.2009.24.1315
15. Bakkum-Gamez J. N., Gonzalez-Bosquet J., Laack N. N., Mariani A., Dowdy S. C., Current issues in the management of endometrial cancer. Mayo Clinic Proceedings 2008 83 1 97 112 2-s2.0-37549061012 10.4065/83.1.97
16. Nieminen T. T., Gylling A., Abdel-Rahman W. M., Nuorva K., Aarnio M., Renkonen-Sinisalo L., Järvinen H. J., Mecklin J., Bützow R., Peltomäki P., Molecular analysis of endometrial tumorigenesis: importance of complex hyperplasia regardless of atypia. Clinical Cancer Research 2009 15 18 5772 5783 2-s2.0-70349439279 10.1158/1078-0432.CCR-09-0506
17. Okuda Y., Nakamura H., Yoshida K., Enomoto H., Uyama H., Hirotani T., Funamoto M., Ito H., Everett A. D., Hada T., Kawase I., Hepatoma-derived growth factor induces tumorigenesis in vivo through both direct angiogenic activity and induction of vascular endothelial growth factor. Cancer Science 2003 94 12 1034 1041 2-s2.0-0346399553 10.1111/j.1349-7006.2003.tb01397.x
18. Tsai H. E., Liu G. S., Kung M. L., Downregulation of heptaoma-derived growth factor contributes to retarded lung metastasis via inhibition of epithelial-mesenchymal transition by systemic POMC gene delivery in melanoma. Molecular Cancer Therapeutics 2013 12 1016 1025
19. Yoshida K., Tomita Y., Okuda Y., Yamamoto S., Enomoto H., Uyama H., Ito H., Hoshida Y., Aozasa K., Nagano H., Sakon M., Kawase I., Monden M., Nakamura H., Hepatoma-derived growth factor is a novel prognostic factor for hepatocellular carcinoma. Annals of Surgical Oncology 2006 13 2 159 167 2-s2.0-31544442216 10.1245/ASO.2006.11.035
20. Yamamoto S., Tomita Y., Hoshida Y., Takiguchi S., Fujiwara Y., Yasuda T., Doki Y., Yoshida K., Aozasa K., Nakamura H., Monden M., Expression of hepatoma-derived growth factor is correlated with lymph node metastasis and prognosis of gastric carcinoma. Clinical Cancer Research 2006 12 1 117 122 2-s2.0-31544432878 10.1158/1078-0432.CCR-05-1347
21. Uyama H., Tomita Y., Nakamura H., Nakamori S., Zhang B., Hoshida Y., Enomoto H., Okuda Y., Sakon M., Aozasa K., Kawase I., Hayashi N., Monden M., Hepatoma-derived growth factor is a novel prognostic factor for patients with pancreatic cancer. Clinical Cancer Research 2006 12 20 6043 6048 2-s2.0-33750712750 10.1158/1078-0432.CCR-06-1064
22. Iwasaki T., Nakagawa K., Nakamura H., Takada Y., Matsui K., Kawahara K., Hepatoma-derived growth factor as a prognostic marker in completely resected non-small-cell lung cancer. Oncology Reports 2005 13 6 1075 1080 2-s2.0-24744463723
23. Chang K., Tai M., Lin J., Wang C., Huang C., Hung C., Chen C., Lu S., Lee C., Changchien C., Hu T., Hepatoma-derived growth factor is a novel prognostic factor for gastrointestinal stromal tumors. International Journal of Cancer 2007 121 5 1059 1065 2-s2.0-34547106044 10.1002/ijc.22803
24. Chen S. C., Kung M. L., Hu T. H., Hepatoma-derived growth factor regulates breast cancer cell invasion by modulating epithelial-mesenchymal transition. The Journal of Pathology 2012 228 158 169
25. Nicolaije K. A., Ezendam N. P., Vos M. C., Follow-up practice in endometrial cancer and the association with patient and hospital characteristics: a study from the population-based PROFILES registry. Gynecologic Oncology 2013 129 2 324 331